Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience

• Main Authors: Miguel Cordero-Coma (Author), Vanesa Calvo-Río (Author), Alfredo Adán (Author), Ricardo Blanco (Author), Carolina Álvarez-Castro (Author), Marina Mesquida (Author), Sara Calleja (Author), Miguel A. González-Gay (Author), José G. Ruíz de Morales (Author)
• Format: Book
• Published: Hindawi Limited, 2014-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients. Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20-38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P=0.009) and mean 1 mm central retinal thickness (317 versus 261.2 μ, P=0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.

Item Description

0962-9351
1466-1861
10.1155/2014/717598